ACE Report Cover
AAHKS 2024: Extended Oral Antibiotics Prevent PJI in High-Risk Cases
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
AAHKS 2024: Extended Oral Antibiotics Prevent PJI in High-Risk Cases .

Extended Oral Antibiotics Prevent PJI in High-Risk Cases: A Prospective, Randomized Controlled Trial

Contributing Authors

B Ji Y Wang L Cao

One hundred eighty-four patients undergoing primary total joint arthroplasty (92 hip and 92 knee cases) were randomized to receive either standard perioperative antibiotic prophylaxis (n=92) or extended oral antibiotic prophylaxis with levofloxacin for 14 days postoperatively (n=92). The primary outcome was the 90-day postoperative incidence of periprosthetic joint infection (PJI). Secondary outcomes included EOA-related complications and cost-effectiveness. The study revealed an identical 90-day PJI incidence of 1.09% (1/92) in both groups, with knee patients showing a 2.17% incidence and no infections observed in hip patients. No EOA-related complications were reported, and the cost-effectiveness model suggested that 333 patients would need EOA to prevent one case of PJI. Overall, the study concluded that EOA did not reduce PJI incidence in high-risk TJA patients within 90 days.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAHKS 2024: Extended Oral Antibiotics Prevent PJI in High-Risk Cases. ACE Report. 2025;307(1):50. Available from: https://myorthoevidence.com/AceReport/Show/aahks-2024-extended-oral-antibiotics-prevent-pji-in-high-risk-cases

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report